Breastfeeding cuts ca risk in high-risk women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 9
Volume 18
Issue 9

Breastfeeding reduces breast cancer risk among women with a family history of breast cancer, according to a study. Observational studies suggest a relationship between lactation and premenopausal breast cancer risk.

Breastfeeding reduces breast cancer risk among women with a family history of breast cancer, according to a study. Observational studies suggest a relationship between lactation and premenopausal breast cancer risk.

In a prospective cohort study of the Nurses' Health Study II involving 60,075 premenopausal women, researchers found that among women with a first-degree relative with breast cancer, those who breastfed had a covariate-adjusted hazard ratio of 0.41. There was no association among women without a family history of breast cancer (Arch Intern Med 169:1364-1371, 2009).

Articles in this issue
Industry Watch
Letter to the Editor
Novel chemoRT regimen ups survival in pancreatic ca
Low expression of MSH2 protein predicts survival in NSCLC
Prostate cancer pilot program stresses patient-oriented care
Quality of life deficits offset benefits of preoperative rectal radiation therapy
CT distinguishes liver cancer mets from lung primary
Prostate cancer patients seek out mind-body care
Who's News
Panitumumab plus FOLFIRI bests FOLFIRI alone as second-line colon ca Rx
A crisis in metastatic breast ca development
Avastin shows active anti-tumor activity in brain cancer
NATCH trial finds no benefit for chemo Rx plus surgery
Lung ca staging stirs debate about noncontrast imaging
Women with metastatic breast cancer fight for a place in the ‘pink parade’
Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Related Content
RAD51 Test May Improve Patient Selection of Olaparib in BRCA1/2 or PALB2 HER2– Breast Cancer

RAD51 Test May Improve Patient Selection of Olaparib in BRCA1/2 or PALB2 HER2– Breast Cancer

Courtney Flaherty
December 20th 2025
Article

“This trial supports the value of a functional RAD51-based HRD assessment to refine patient selection for PARP inhibitors,” said Isabel Pimentel, MD.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Subgroup data from the phase 3 DESTINY-Breast05 trial further characterize the clinical benefit of T-DXd over T-DM1 in this breast cancer population.

T-DXd Improves iDFS Across HER2+ Early Breast Cancer Subgroups

Chris Ryan
December 19th 2025
Article

Subgroup data from the phase 3 DESTINY-Breast05 trial further characterize the clinical benefit of T-DXd over T-DM1 in this breast cancer population.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Data from the ELEVATE trial may support elacestrant as an endocrine backbone in ER-positive, HER2-negative breast cancer.

Elacestrant Regimens Yield Meaningful PFS in ER+/HER2– Breast Cancer

Courtney Flaherty
December 17th 2025
Article

Data from the ELEVATE trial may support elacestrant as an endocrine backbone in ER-positive, HER2-negative breast cancer.

Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer

Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer

Ariana Pelosci
December 17th 2025
Article

A label for imlunestrant/abemaciclib in ER+/HER2– advanced breast cancer with ESR1 mutations will be sought.